Claims for Patent: 12,116,368
✉ Email this page to a colleague
Summary for Patent: 12,116,368
| Title: | Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto |
| Abstract: | The present invention discloses a novel p-toluenesulfonic acid salt and a crystalline polymorphic Form 1 of said salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharmaceutical composition containing the same, as well as preparations and uses thereof. The present invention also discloses a novel phosphoric acid salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, pharma-ceutical composition containing the same, as well as preparations and uses thereof. |
| Inventor(s): | Brian Matthew Samas, Yong Tao, Douglas James Critcher, David Sydney Bernard Daniels, Kevin Paul Girard, Gregory Scott Goeken, Peter Robert Rose |
| Assignee: | Pfizer Corp SRL |
| Application Number: | US17/286,018 |
| Patent Claims: |
1. A p-toluenesulfonic acid salt of 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, having a powder X-ray diffraction pattern comprising peaks, in terms of 2θ, at 11.4, 14.1, 16.7, 17.9 and 21.6° 2θ±0.2° 2θ. 2. The crystalline form of claim 1, having a powder X-ray diffraction pattern comprising peaks, in terms of 2θ, at 11.4, 16.7, 17.9° 2θ±0.2° 2θ and solid state 13C nuclear magnetic resonance chemical shifts selected from the group consisting of 131.6, 147.9 ppm±0.2 ppm. 3. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising peaks, in terms of 2θ, at 11.4, 16.7, 17.9° 2θ±0.2° 2θ and a set of Raman bands at 1617, 1601 cm−1±2 cm−1. 4. The crystalline form of claim 1 having a powder X-ray diffraction pattern comprising peaks, in terms of 2θ, at 11.4, 16.7, 17.9° 2θ±0.2° 2θ, a set of Raman bands at 1617, 1601 cm−1±2 cm−1 and solid state 13C nuclear magnetic resonance chemical shifts selected from the group consisting of 131.6, 147.9 ppm±0.2 ppm. 5. A method of treating psoriasis, comprising administering to a subject suffering from said disease or condition an effective amount of a composition comprising the salt of claim 1. 6. A method of treating vitiligo, comprising administering to a subject suffering from said disease or condition an effective amount of a composition comprising the salt of claim 1. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
